Cobicistat: A new boost for the treatment of human immunodeficiency virus infection

Pharmacotherapy

Volumn 33, Issue 10, 2013, Pages 1107-1116

  Shah, Bhavik M ^a   Schafer, Jason J ^a   Priano, James ^a   Squires, Kathleen E ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

antiretrovirals; booster; cobicistat; GS 9350; HIV; human immunodeficiency virus; pharmacokinetic enhancer; ritonavir

Indexed keywords

ALFUZOSIN; AMIODARONE; ATAZANAVIR; COBICISTAT; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; CONIVAPTAN; CREATININE; DARUNAVIR; DESIPRAMINE; DIGOXIN; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; ETRAVIRINE; FAMOTIDINE; MIDAZOLAM; OMEPRAZOLE; RIFAMPICIN; RITONAVIR; SIMVASTATIN;

AREA UNDER THE CURVE; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; KIDNEY FUNCTION; MULTICENTER STUDY (TOPIC); NAUSEA; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW;

ANTIRETROVIRALS; BOOSTER; COBICISTAT; GS-9350; HIV; HUMAN IMMUNODEFICIENCY VIRUS; PHARMACOKINETIC ENHANCER; RITONAVIR;

ANTI-HIV AGENTS; CARBAMATES; CYTOCHROME P-450 CYP3A; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HIV INFECTIONS; HUMANS; RITONAVIR; THIAZOLES;

EID: 84885222034     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1237     Document Type: Review

References (37)

1. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, March 2012. Available from http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/ adultandadolescentgl.pdf. Accessed October 5, 2012.
2. DeJesus E, Young B, Morales-Ramirez JO, et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr 2009; 51: 163-74.
3. Sax PE, Meyers JL, Mugavero M, Davis KL,. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS ONE 2012; 7: e31591.
4. Airoldi M, Zaccaelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence 2010; 4: 115-25.
5. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 2010; 87: 322-9.
6. Youle M,. Overview of boosted protease inhibitors in treatment- experienced HIV-infected patients. J Antimicrob Chemother 2007; 60: 1195-205.
7. Gallant JE,. Protease-inhibitor boosting in the treatment-experienced patient. AIDS Rev 2004; 6: 226-33.
8. Shafran SD, Mashinter LD, Roberts SE,. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med 2005; 6: 421-5.
9. Foisy MM, Yakiwchuk EM, Hughes CA,. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008; 42: 1048-59.
10. Law D, Schmitt EA, Marsh KC, et al. Ritonavir-PEG 8000 amorphous solid dispersions: In vitro and in vivo evaluations. J Pharm Sci 2004; 93: 563-70.
11. Elion R, Cohen C, Gathe J, et al. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dosed emtricitabine/ tenofovir df in the initial treatment of HIV infection. AIDS 2011; 25: 1881-6.
12. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr 2012; 61: 32-40.
13. Department of Health and Human Services. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents recommends a fixed-dose combination product of elvitegravir/cobicistat/tenofovir/emtricitabine as an alternative regimen in antiretroviral treatment-naïve individuals with HIV-1 infection. Available from http://aidsinfo.nih.gov/contentfiles/AdultARVStatementOnEVG- COBI-TDF-FTC.pdf. Accessed October 7, 2012.
14. German P, Mathias A, Wei L, Murray B, Warren D, Kearney B,. The effect of cobicistat on cytochrome P450 2D6, 2B6 and P-glycoprotein using phenotypic probes (abstract O-01). Presented at the 12th International Workshop on Clinical Pharmacology of HIV Therapy, Miami, FL, April 13-15, 2011.
15. Xu L, Liu H, Murray B, et al. Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med Chem Lett. 2010; 1: 209-13.
16. Rathbun C, Liedtke M,. Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management. Pharmaceutics. 2011; 3: 745-81.
17. Lexi-Comp OnlineTM, Lexi-Drugs Online™, Hudson, Ohio: Lexi-Comp, Inc.; May 1, 2012.
18. ®), 2011. Available from http://hivinsite.ucsf.edu/insite?page= ar-00-02¶m=8&post=4. Accessed May 1, 2012.
19. Mathias A, Koziara J, Wei L, Warren D, Kearney BP,. Effect of acid reducing agents on the relative bioavailability and pharmacokinetics of cobicistat-boosted elvitegravir (abstract P-13). Presented at the 12th International Workshop on Clinical Pharmacology of HIV Therapy, Miami, FL, April 13-15, 2011.
20. German P, Warren D, West S, Hui J, Kearney BP,. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dosed combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr 2010; 55: 323-9.
21. Ramanathan S, Warren D, Wei L, Kearney BP,. Pharmacokinetic boosting of atazanavir with the pharmacoenhancer GS-9350 versus ritonavir (abstract 614). Presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, September 12-15, 2009.
22. Mathias A, Liu HC, Warren D, Sekar V, Kearney BP,. Relative bioavailability and pharmacokinetics of darunavir when boosted with the pharmacoenhancer GS-9350 versus ritonavir (abstract 28). Presented at the 11th International Workshop on Clinical Pharmacology of HIV Therapy, Sorrento, Italy, April 7-9, 2010.
23. Ramanathan S, Wang H, Szwarcberg J, Kearney BP,. Twice-daily effects differ with darunavir and tipranavir (abstract P-08). Presented at the 13th International Workshop on Clinical Pharmacology of HIV Therapy, Barcelona, Spain, April 16-18, 2012.
24. Cohen C, Elion R, Ruane P, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 2011; 25: F7-12.
25. Lepist EI, Murray BP, Tong L, Roy A, Bannister R, Ray AS,. Effect of cobicistat and ritonavir on proximal renal tubular cell uptake and efflux transporters (abstract A1-1724). Presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2011.
26. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379: 2439-48.
27. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379: 2429-38.
28. Gilead Sciences, Inc. Stribild package insert. Foster City, CA; 2012.
29. Bristol-Myers Squibb and Gilead Sciences, Inc. Press release: Bristol-Myers Squibb and Gilead Sciences announce licensing agreement for development and commercialization of new fixed-dose combination pill for people living with HIV. Available from http://www.gilead.com/pr-1621754. Accessed May 24, 2012.
30. Gilead Sciences, Inc. A phase 2, randomized, double-blinded study of the safety and efficacy of darunavir/cobicistat/emtricitabine/GS-7340 single tablet regimen versus cobicistat-boosted darunavir plus emtricitabine/tenofovir disoproxil fumarate fixed dose combination in HIV-1 infected, antiretroviral treatment naïve adults. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT01565850?term= cobicistat&rank=2. NLM identifier: NCT01565850.
31. Gilead Sciences, Inc. A phase 3, randomized, double-blind study to evaluate the safety and efficacy of GS-9350-boosted atazanavir versus ritonavir-boosted atazanavir each administered with emtricitabine/tenofovir disoproxil fumarate in HIV-1 infected, antiretroviral treatment-naïve adults. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://www.clinicaltrials.gov/ct2/show/NCT01108510?term= gilead+atazanavir&rank=3. NLM identifier: NCT01108510. Accessed April 26, 2012.
32. Gilead Sciences, Inc. Phase 3b open-label, single arm study to evaluate the safety and efficacy of cobicistat-boosted darunavir in HIV infected adults. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT01440569?term=cobicistat&rank=5. NLM identifier: NCT01440569. Accessed May 20, 2012.
33. Ramanathan S, Wang H, Custodio J, et al. Pharmacokinetics of EVG/COBI/FTC/TDF single tablet regimen following treatment with EFV/FTC/TDF (Atripla) in healthy subjects (abstract O-21). Presented at the 13th International Workshop on Clinical Pharmacology of HIV Therapy, Barcelona, Spain, April 16-18, 2012.
34. Gilead Sciences, Inc. Phase 3b open label study to evaluate switching from regimens consisting of a non-nucleoside reverse transcriptase inhibitor plus emtricitabine and tenofovir df to the elvitegravir/cobicistat/ emtricitabine/tenofovir df single-tablet regimen in virologically suppressed, HIV 1 infected patients. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT01495702?term= cobicistat&rank=6. NLM identifier: NCT01495702. Accessed May 20, 2012.
35. Gilead Sciences, Inc. Open-label pilot study to evaluate switching from a regimen consisting of raltegravir plus emtricitabine/tenofovir df fixed-dose combination to the elvitegravir/cobicistat/emtricitabine/tenofovir df single-tablet regimen in virologically suppressed, HIV 1 infected patients. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT01495702?term=cobicistat&rank=7. NLM identifier: NCT01533259. Accessed May 20, 2012.
36. Gilead Sciences, Inc. Study to evaluate switching from regimens consisting of a ritonavir-boosted protease inhibitor plus emtricitabine/ tenofovir df fixed-dose combination to the elvitegravir/cobicistat/ emtricitabine/tenofovir df single-tablet regimen in virologically suppressed, HIV 1 infected patients. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT01495702?term= cobicistat&rank=5. NLM identifier: NCT01475838. Accessed May 20, 2012.
37. Gilead Sciences, Inc. Cobicistat-containing highly active antiretroviral regimens in HIV-1 infected patients with mild to moderate renal impairment. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT01495702?term=cobicistat&rank=3. NLM identifier: NCT01363011. Accessed May 20, 2012.